Polyherbal preparation LIV 52 Protec reclassified as Ayurvedic Medicament under CETH 300339 not Animal Feed Supplement

CESTAT Bangalore ruled that polyherbal preparation LIV 52 Protec was misclassified by appellant as Animal Feed Supplement under CETH 230990/23099010. The tribunal held it should be classified as Ayurvedic Medicament under CETH 300339/30049011, noting the product contains hepatoprotective herbs without vitamins/minerals typical of feed supplements. Extended period of limitation was rejected as department was aware of facts through ER-1 returns and audits showed no suppression. Penalties under Section 11AC and Rule 25 were dropped given classification dispute nature. Appeal disposed.

---

---

ISSUES PRESENTED AND CONSIDERED

1. Whether the polyherbal liquid product is classifiable as a "preparation of a kind used in animal feeding" (Chapter 23) or as a "medicament/Ayurvedic medicament" (Chapter 30) for the relevant periods.

2. Whether HSN Section/Chapter Notes and explanatory notes (esp. Notes to Chapter 30.03/30.04 and exclusion in 30.04) apply to determine classification of a polyherbal preparation not put up solely as nutritive supplement.

3. The evidentiary weight of chemical analysis, product literature, composition and common parlance in determining therapeutic/prophylactic character of the product and the impact of competing user/trader letters and label declarations.

4. Whether invocation of the extended limitation period (proviso to Section 11A / suppression) is sustainable in view of ER-1 returns, departmental audits and prior approvals.

5. Whether penalties under statutory provisions (extended-period penalty and Rule 25 penalties) are maintainable when classification issue is determinative.

6. Whether regulatory/licensing requirements (drug licence) are preconditions to classification under the Tariff Act.

ISSUE-WISE DETAILED ANALYSIS

Issue 1 - Classification: Chapter 23 (animal feed) vs Chapter 30 (medicament/Ayurvedic medicament)

Legal framework: Tariff headings for "preparations of a kind used in animal feeding" (Chapter 23, esp. 2309/23099010) and for "medicaments...for therapeutic or prophylactic uses" (Chapter 30, esp. 3003/3004 with subheadings for Ayurvedic medicaments) govern classification. HSN explanatory notes and Section/Chapter Notes guide the functional test (use, composition, presentation).

Precedent Treatment: The Court considered prior authorities where similar products were classified either as medicaments or feed supplements and specifically examined how prior decisions (including those distinguishing facts on lab reports and common parlance) were applied to classification disputes.

Interpretation and reasoning: The Tribunal applied a functional test - whether the product's properties and mode of use primarily effect therapeutic or prophylactic outcomes (treatment/prevention of liver ailments) rather than purely nutritional supplementation. It accepted the chemical analysis (Indian Institute of Chemical Technology/Herboprint) and product literature showing directions, dosage and therapeutic claims. It contrasted ingredient profile (herbal ingredients with known hepatoprotective activity) with the nature of typical feed supplements (vitamins, minerals, proteins) which the product lacks. The Tribunal also compared the product to a separately marketed, duty-paid veterinary formulation from the same manufacturer with substantially similar composition and use, strengthening medicament classification.

Ratio vs. Obiter: Ratio - a polyherbal liquid with demonstrated hepato-protective/prophylactic properties, dosage instructions, and ingredients cited in authoritative Ayurvedic texts is classifiable as a medicament under Chapter 30 rather than a feed supplement under Chapter 23. Obiter - observations about the breadth of pharmacological definitions of "drug" and detailed exposition of pharmacology/therapeutics beyond what was necessary to classify.

Conclusion: The product is rightly classifiable under Chapter Sub-heading 300339 up to Feb 2005 and under 30049011 from March 2005 onward as an Ayurvedic medicament; classification under Chapter 23 is incorrect.

Issue 2 - Application of HSN Notes to polyherbal preparations (Ch.30.03/30.04)

Legal framework: Explanatory Notes to HSN Chapter 30.03/30.04 indicate coverage of medicaments consisting of two or more constituents used for therapeutic or prophylactic uses; distinction between headings 30.03 and 30.04 depends on whether product is put up in measured doses/retail packing. Footnote excludes mere food supplements lacking any indication for prevention/treatment of disease.

Precedent Treatment: The Tribunal relied on the HSN Notes as interpreted in prior rulings but applied the Notes to the facts before it rather than adopting any blanket rule from precedent.

Interpretation and reasoning: Because the product is accompanied by dosage instructions, directions for use and literature indicating use for hepatic disorders (therapeutic/prophylactic), it falls within the scope of medicaments covered by the HSN Notes. The explanatory exclusions for mere food supplements do not apply where there are therapeutic indications and prophylactic use.

Ratio vs. Obiter: Ratio - HSN explanatory notes require assessment of therapeutic/prophylactic use and packaging/dosage presentation; where such indicia exist, Chapter 30 applies. Obiter - extensive textual exposition of HSN scope beyond the narrow application in this case.

Conclusion: HSN Notes support classification under Chapter 30 for the product on the facts found.

Issue 3 - Evidentiary weight: chemical analysis, literature, composition, common parlance vs letters/label disclaimers

Legal framework: Classification depends on objective characteristics - composition, properties, intended use, presentation and common parlance; evidentiary material may include laboratory analysis, authoritative texts, marketing literature and trade perception.

Precedent Treatment: The Court engaged with prior cases where departmental laboratory reports or lack thereof were decisive; it distinguished those authorities where revenue's lab report found absence of Ayurvedic descriptors and where appellants produced documentary market/user evidence.

Interpretation and reasoning: The Tribunal gave decisive weight to independent chemical analysis confirming presence of herbal ingredients and hepato-protective properties and to literature showing dosage and therapeutic claims. It found trader/veterinarian letters asserting feed-supplement character were general and insufficiently probative compared to scientific analysis and evidence of marketing as Ayurvedic medicament in other media. A packaging statement "Not for medicinal use" was not accepted as determinative where other objective indicia (composition, literature, dosage, lab report, common parlance via broader publicity) point to medicament use.

Ratio vs. Obiter: Ratio - independent scientific analysis and documentary indicia of therapeutic/prophylactic use can outweigh general market letters and label declarations when determining classification. Obiter - commentary on social media/YouTube as evidence of common parlance.

Conclusion: The chemical analysis, composition and literature together establish therapeutic/prophylactic character; competing letters and packaging disclaimers do not rebut that evidence.

Issue 4 - Invocation of extended period (suppression) and limitation

Legal framework: Extended period for recovery of duty requires wilful suppression of facts; limitation and invocation of extended period examined against conduct (returns filed), departmental approvals and audits.

Precedent Treatment: The Tribunal considered authorities holding that where revenue had knowledge or audits did not raise the issue, extended period may not be invoked.

Interpretation and reasoning: The appellant filed ER-1 returns declaring the product and had classification on approved lists; departmental audits and approvals were conducted without objection; there was no contemporaneous indication that the appellant suppressed facts. Given departmental awareness and absence of pointed audit findings, extended period invocation for May 2002-Apr 2007 was held unsustainable. However, for the same period the Tribunal still confirmed normal period demand (i.e., without extended period) because classification under Chapter 30 was established.

Ratio vs. Obiter: Ratio - extended period cannot be invoked where records (returns, audit) demonstrate that revenue had constructive knowledge and no wilful suppression is established. Obiter - detailed recitation of audit purpose and limits of officer visits.

Conclusion: Extended period invocation for May 2002-Apr 2007 is not legally sustainable; normal-period demand remains confirmed.

Issue 5 - Penalties (Section 11AC and Rule 25) - sustainability where classification disputed

Legal framework: Penalties for misclassification/suppression are imposed under specified provisions when culpability or contravention established; however penalties may be inappropriate where bona fide classification issues exist.

Precedent Treatment: Penalties are to be assessed in light of the nature of the issue (classification dispute vs. fraud/suppression) and the facts surrounding knowledge and conduct.

Interpretation and reasoning: Because the dispute centered on classification with evidentiary conflict and because extended period (wilful suppression) could not be sustained for the earlier period, the Tribunal treated penalties as not legally sustainable. The Tribunal distinguished punitive treatment where the appellant had contemporaneous returns and prior departmental interactions.

Ratio vs. Obiter: Ratio - penalties under Section 11AC and Rule 25 are not sustainable where classification is a genuine issue and extended period/suppression is not proved. Obiter - general comments on when penalties would be appropriate.

Conclusion: Imposed penalties under Section 11AC and Rule 25 are dropped.

Issue 6 - Relevance of drug licence/regulatory approvals to classification

Legal framework: Classification under the Tariff Act is determined by function, composition and use; regulatory licensing is a separate statutory regime.

Precedent Treatment: Courts have held that absence/presence of regulatory licence does not determine tariff classification though it may be relevant to compliance with other laws.

Interpretation and reasoning: The Tribunal held that the need for a drug licence (if any) is not a precondition to classify an item under Chapter 30. Licensing obligations arise under other statutes and do not alter tariff classification, which depends on objective product characteristics and uses.

Ratio vs. Obiter: Ratio - drug licence requirement is irrelevant to tariff classification; Obiter - procedural consequences of licensing not explored further.

Conclusion: Absence of a drug licence does not preclude classification as a medicament under Chapter 30.

---